In a retrospective study of 376 patients with epidermal growth factor receptor (EGFR) wild-type advanced NSCLC, it was discovered that combining YFSJF with chemotherapy could improve the mOS compared to chemotherapy alone [11]. Here, EGFR is linked to non-small cell lung carcinoma.